REFERENCES
[1] Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, Estes NA 3rd, Field ME, Goldberger ZD, Hammill SC, Indik JH, Lindsay BD, Olshansky B, Russo AM, Shen WK, Tracy CM, Al-Khatib SM; Evidence Review Committee Chair‡. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016 Apr 5;133(14):e506-74.
[2] Orejarena LA, Vidaillet H Jr, DeStefano F, Nordstrom DL, Vierkant RA, Smith PN, Hayes JJ. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998 Jan;31(1):150-7.
[3] Kitzlerová E, Anders M, Kautzner J, Dohnalová A. Evaluation of psychopathology in patients with paroxysmal supraventricular tachycardia. Exp Clin Cardiol. 2007 Spring;12(1):42-5.
[4] Domschke K, Stevens S, Pfleiderer B, Gerlach AL. Interoceptive sensitivity in anxiety and anxiety disorders: an overview and integration of neurobiological findings. Clin Psychol Rev. 2010 Feb;30(1):1-11.
[5] Stewart SH, Buffett-Jerrott SE, Kokaram R. Heartbeat awareness and heart rate reactivity in anxiety sensitivity: a further investigation. J Anxiety Disord. 2001 Nov-Dec;15(6):535-53.
[6] Lessmeier TJ, Gamperling D, Johnson-Liddon V, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Unrecognized paroxysmal supraventricular tachycardia. Potential for misdiagnosis as panic disorder. Arch Intern Med. 1997 Mar 10;157(5):537-43.
[7] Papiashvili G, Tabagari-Bregvadze N, Brugada J. INFLUENCE OF CATHETER ABLATION OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA ON PATIENTS’ ANXIETY. Georgian Med News. 2018 Feb;(Issue):58-60.
[8] Yildirim O, Yontar OC, Semiz M, Erdem A, Canan F, Yontar G, Kuğu N. The effect of radiofrequency ablation treatment on quality of life and anxiety in patients with supraventricular tachycardia. Eur Rev Med Pharmacol Sci. 2012 Dec;16(15):2108-12.
[9] Domschke K, Kirchhof P, Zwanzger P, Gerlach AL, Breithardt G, Deckert J. Coincidence of paroxysmal supraventricular tachycardia and panic disorder: two case reports. Ann Gen Psychiatry. 2010 Apr 12;9:13.
[10] Papiashvili G, Tabagari-Bregvadze N, Brugada J. IMPACT OF RADIOFREQUENCY CATHETER ABLATION ON HEALTH-RELATED QUALITY OF LIFE ASSESSED BY THE SF-36 QUESTIONNAIRE IN PATIENTS WITH PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA. Georgian Med News. 2018 Feb;(Issue):54-57.
[11] American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.).
[12] Spector P, Reynolds MR, Calkins H, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol. 2009 Sep 1;104(5):671-7.
[13] Calkins H, Yong P, Miller JM, Olshansky B, Carlson M, Saul JP, Huang SK, Liem LB, Klein LS, Moser SA, Bloch DA, Gillette P, Prystowsky E. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation. 1999 Jan 19;99(2):262-70.
[14] Meissner A, Stifoudi I. Sustained high quality of life in a 5 year long term follow-up after successful ablation for SVT. Int J Med Sci. 2009; 6(1): 546-50.
[15] Parizek P, Haman L. Long-term outcome of catheter ablation therapy of SVT. Vnitr Lek. 2011; 57 (6):546-50.
[16] Marshall DA, O’Brien BJ, Nichol G. Review of economic evaluations of RF catheter ablations for cardiac arrhythmias. Can J Cardiol. 2003; 19(11):1285-304.
[17] Cheng CH. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. Ann Intern Med 2000; 133: 864-76.
[18] Hogenhuis W. Cost-effectivess of radiofrequency ablation compared with other strategies in Wolff-Parkinson-White Syndrome. Cirulation 1993; 88:11437-46.
[19] O’Callaghan PA. Symptomatic improvement after radiofrequency catheter ablation for typical atrial flutter. Heart 2001; 86:167-71.
[20] WHOQOL Reference - World Health Organization (1996) WHO-BREF: Introduction, administration, scoring and generic version of the assessment. 1996. Geneva: WHO. http://www.who.int/mental_health/media/en/76.pdf
[21] Spielberger, C. D., Gorsuch, R. L., Lushene, R., Vagg, P. R., & Jacobs, G. A. (1983). Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press.
[22] Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.
[23] Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association. Am J Psychiatry. 1998 May;155(5 Suppl):1-34.
[24] National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: management in primary, secondary and community care. January 2011. http://www.nice.org.uk/Guidance/CG113. Accessed May 20, 2021.
[25] Hoge EA, Ivkovic A, Fricchione GL. Generalized anxiety disorder: diagnosis and treatment. BMJ. 2012;345:e7500.
[26] Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;(12):CD008120.
[27] Kaczkurkin AN, Foa EB. Cognitive-behavioral therapy for anxiety disorders: an update on the empirical evidence. Dialogues Clin Neurosci. 2015 Sep;17(3):337-46.